<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUOCINOLONE ACETONIDE- fluocinolone acetonide oil </strong><br>Seton Pharmaceuticals<br></p></div>
<h1>Fluocinolone Acetonide 0.01% Topical oil<br>(Scalp Oil)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">For Dermatologic Use Only-        <span class="Bold">NDC 13925-507-04</span><br>Not for Oral, Ophthalmic, or Intravaginal Use-</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) contains fluocinolone acetonide {(6α, 11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone}, a synthetic corticosteroid for topical dermatologic use. Chemically, fluocinolone acetonide is C<span class="Sub">24</span>H<span class="Sub">30</span>F<span class="Sub">2</span>O<span class="Sub">6</span>. It has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d55d846-c833-4040-b02d-ac7783311dd6&amp;name=16e3bb49-35e7-40b9-9004-58f17a71dea6-01.jpg"></div>
<p>Fluocinolone acetonide  has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.</p>
<p>Each gram of Fluocinolone Acetonide 0.01% Topical Oil contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils which contain isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, refined peanut oil NF and fragrances.</p>
<p>Each packaged product contains 2 shower caps. The shower cap is made of low density polyethylene material with rubber elastic.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Like other topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A<span class="Sub">2</span> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<span class="Sub">2</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s3"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics:</span> The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusion of topical corticosteroids can enhance penetration. Topical corticosteroids can be absorbed from normal intact skin. Also, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and/or other disease processes in the skin can increase percutaneous absorption.</p>
<p>Fluocinolone Acetonide 0.01% Topical Oil  is in the low to medium range of potency as compared with other topical corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s4"></a><a name="section-3.2"></a><p></p>
<h2>CLINICAL STUDIES</h2>
<p class="First">In a vehicle-controlled study for the treatment of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> of the scalp in adults, after 21 days of treatment, 60% of patients on active treatment and 21% of patients on the drug vehicle had excellent to cleared clinical response.</p>
<p>Open-label safety studies on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, and baseline body surface area involvement greater than 75% in 18 patients, and 50% to 75% in 15 patients, were treated with Fluocinolone Acetonide 0.01% Topical Oil  twice daily for 4 weeks. Morning pre-stimulation cortisol level and post-Cortrosyn stimulation cortisol level were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 ug/dL; normal: cortisol &gt; 7 ug/dL) but all had normal responses to 0.25 mg of Cortrosyn stimulation (cortisol &gt; 18 ug/dL).</p>
<p>A clinical study was conducted to assess the safety of Fluocinolone Acetonide 0.01% Topical Oil, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, 6 to 17 years of age. Of the 13 patients, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the responses to both prick test and patch test utilizing refined peanut oil NF, Fluocinolone Acetonide 0.01% Topical Oil  and histamine/saline controls, on the 13 individuals. These subjects were also treated with Fluocinolone Acetonide 0.01% Topical Oil  twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to Fluocinolone Acetonide 0.01% Topical Oil  and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> after 5 days of Fluocinolone Acetonide 0.01% Topical Oil   use. Importantly, the bulk peanut oil NF, used in Fluocinolone Acetonide 0.01% Topical Oil   is heated at 475° F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>INDICATION AND USAGE</h1>
<p class="First">Fluocinolone Acetonide 0.01% Topical Oil is a low to medium potency corticosteroid indicated:</p>
<p>In adult patients for the treatment of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> of the scalp (Scalp Oil).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) is contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the preparation.</p>
<p>This product contains refined peanut oil NF (see <a href="#s7">PRECAUTIONS</a> section).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s8"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.</p>
<p>Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests.</p>
<p>If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Infrequently, signs and symptoms of glucocorticoid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.</p>
<p>Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> ratios. (See <a href="#s14">PRECAUTIONS-Pediatric use</a>)</p>
<p><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> to any component of topical corticosteroids is usually diagnosed by a <span class="Italics">failure to heal</span> rather than noting a clinical exacerbation, which may occur with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic testing. One peanut sensitive child experienced a flare of his <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> after 5 days of twice daily treatment with Fluocinolone Acetonide 0.01% Topical Oil  (See <a href="#s3">CLINICAL STUDIES</a> section).</p>
<p>If wheal and flare type reactions (which may be limited to <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) or other manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> develop, Fluocinolone Acetonide 0.01% Topical Oil  should be discontinued immediately and appropriate therapy instituted.</p>
<p>If concomitant <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Fluocinolone Acetonide 0.01% Topical Oil should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.</p>
<p>Fluocinolone Acetonide 0.01% Topical Oil is formulated with 48% refined peanut oil NF. Peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million.</p>
<p>Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil for peanutsensitive individuals.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s9"></a><a name="section-6.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span>  Patients using topical corticosteroids should receive the following information and instructions:</p>
<ol>
<li>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. In case of contact, wash eyes liberally with water.</li>
<li>This medication should not be used for any disorder other than that for which it was prescribed.</li>
<li>Patients should promptly report to their physician any worsening of their skin condition.</li>
<li>Parents of pediatric patients should be advised not to use Fluocinolone Acetonide 0.01% Topical Oil  in the treatment of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>. Fluocinolone Acetonide 0.01% Topical Oil  should not be applied to the diaper area as diapers or plastic pants may constitute occlusive dressing.</li>
<li>This medication should not be used on the face, underarm, or groin unless directed by the physician.</li>
<li>As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s10"></a><a name="section-6.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests:</span> The following tests may be helpful in evaluating patients for HPA axis suppression:</p>
<p>ACTH stimulation test<br>A.M. plasma cortisol test<br>Urinary free cortisol test</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s11"></a><a name="section-6.4"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, mutagenesis, and impairment of fertility:</span> Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Fluocinolone Acetonide 0.01% Topical Oil. Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide, the active ingredient in Fluocinolone Acetonide 0.01% Topical Oil. Some corticosteroids have been found to be genotoxic in various genotoxicity tests (i.e. the <span class="Italics">in vitro</span> human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the <span class="Italics">in vivo</span> mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test and the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> gene mutation assay).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s12"></a><a name="section-6.5"></a><p></p>
<div class="Section" data-sectionCode="34077-8">
<a name="s12.1"></a><a name="section-6.5.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy: Teratogenic effects: Pregnancy category C:</span> Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</p>
<p>There are no adequate and well-controlled studies in pregnant women on teratogenic effects from Fluocinolone Acetonide 0.01% Topical Oil. Therefore, Fluocinolone Acetonide 0.01% Topical Oil  should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s13"></a><a name="section-7"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fluocinolone Acetonide 0.01% Topical Oil  is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s14"></a><a name="section-8"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Fluocinolone Acetonide 0.01% Topical Oil  may be used twice daily for up to 4 weeks in pediatric patients 2 years and older with moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>. Fluocinolone Acetonide 0.01% Topical Oil  should not be applied to the diaper area.</p>
<p>Application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, and <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span>, which may be irreversible. The smallest amount of drug needed to cover the affected areas should be applied. Long term safety in the pediatric population has not been established.</p>
<p>Fluocinolone Acetonide 0.01% Topical Oil  is not recommended for use on the face (see <a href="#s15">ADVERSE REACTIONS</a> section).</p>
<p>Because of a higher ratio of skin surface area to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, children are at a greater risk than adults of HPA-axis-suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span> have been reported with inappropriate use of topical corticosteroids in infants and children. (see <a href="#s7">PRECAUTIONS</a>).</p>
<p>HPA axis suppression, Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in children receiving topical corticosteroids. Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> ratios. Manifestations of adrenal suppression in children include linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.</p>
<p>Fluocinolone Acetonide 0.01% Topical Oil  is formulated with 48% refined peanut oil NF. Peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million. </p>
<p>Physicians should use caution in prescribing Fluocinolone Acetonide 0.01% Topical Oil  for peanut sensitive individuals.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following local adverse reactions have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of  occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>. One peanut sensitive child experienced a flare of his <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> after 5 days of twice daily treatment with Fluocinolone Acetonide 0.01% Topical Oil.</p>
<p>A post marketing (open-label) safety study was conducted in 58 children to evaluate the local safety of Fluocinolone Acetonide 0.01% Topical Oil  when applied twice daily for 4 weeks to the face in children (2 to 12 years) with moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> (see <a href="#table1">Table of Incidence of Adverse Events</a>).</p>
<a name="table1"></a><table width="80%">
<caption><span>Incidence of Adverse Events (%) N=58</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<td class="Lrule" align="center">
<span class="Bold">Adverse Event (AE)</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Lrule" align="center">
<span class="Bold"># of patients (%)</span><br>
</td>
<th class="Lrule" align="center">Day 14</th>
<td class="Lrule" align="center">
<span class="Bold">Day 28</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold">Day 56</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="Bold">The number of individual adverse events reported does not necessarily reflect the number of individual subjects, since one subject could have multiple reporting of an adverse event.</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd><span class="Bold">End of Treatment</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="Bold">Four Weeks Post Treatment</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Any AE</td>
<td class="Lrule" align="center">15 (25.9)</td>
<td class="Lrule" align="center">6 (10.3)</td>
<td class="Lrule" align="center">7 (12.1)</td>
<td class="Lrule Rrule" align="center">7 (12.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">Telangiectasia</span></td>
<td class="Lrule" align="center">5 (8.6)</td>
<td class="Lrule" align="center">3 (5.2)</td>
<td class="Lrule" align="center">4 (6.9)</td>
<td class="Lrule Rrule" align="center">2 (3.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Lrule" align="center">3 (5.2)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">3 (5.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></td>
<td class="Lrule" align="center">3 (5.2)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">3 (5.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Irritation</td>
<td class="Lrule" align="center">3 (5.2)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">3 (5.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Burning</td>
<td class="Lrule" align="center">3 (5.2)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">3 (5.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Hypopigmentation</td>
<td class="Lrule" align="center">2 (3.5)</td>
<td class="Lrule" align="center">2 (3.5)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Shiny skin</td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Secondary <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">1 (1.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">Papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">1 (1.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4197127" conceptname="Keratosis pilaris">Keratosis pilaris</span></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">1 (1.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Facial herpes simplex</td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">Acneiform eruption</span></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">Ear infection</span></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center">1 (1.7)</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s16"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Topically applied Fluocinolone Acetonide 0.01% Topical Oil  can be absorbed in sufficient amounts to produce systemic effects (see <a href="#s7">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s17"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Fluocinolone Acetonide 0.01% Topical Oil  for scalp <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> in adults (Scalp Oil):</p>
<p>For the treatment of scalp <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, wet or dampen hair and scalp thoroughly. Apply a thin film of Fluocinolone Acetonide 0.01% Topical Oil  on the scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight or for a minimum of 4 hours before washing off. Wash hair with regular shampoo and rinse thoroughly.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s18"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) is supplied in bottles containing 4 fluid ounces.</p>
<p>It is labeled as Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) (<span class="Bold">NDC # 13925-507-04</span>).</p>
<p>Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) is supplied with 2 shower caps.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s19"></a><a name="section-12.1"></a><p></p>
<h2></h2>
<p class="First">Keep tightly closed. Store at 25°C (68° to 77°F); excursions permitted to 15°–30°C (59°–86° F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold">CAUTION: Rx only</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2></h2>
<p class="First">MANUFACTURED BY: <br>Hill Dermaceuticals, Inc. <br>Sanford, Florida 32773</p>
<p>FOR: <br>Seton Pharmaceuticals<br>Manasquan, NJ 08736<br>1-800-510-3401</p>
<p>Code: 171G242-0<br>Date: 06/2013</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 118.28 mL Label</h1>
<p class="First"><span class="Bold">NDC 13925-507-04</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">FLUOCINOLONE<br>ACETONIDE<br> 0.01% TOPICAL <br>OIL</span></p>
<p><span class="Bold">(SCALP OIL)</span></p>
<p><span class="Bold">FOR TOPICAL USE ONLY<br>NOT FOR ORAL, OPHTHALMIC <br>OR INTRAVAGINAL USE</span></p>
<p><span class="Bold">SHAKE WELL BEFORE USE</span></p>
<p><span class="Bold">Net Contents 118.28 mL <br>(4 fl. oz.)</span></p>
<p><span class="Bold">SETON<br>PHARMACEUTICALS</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL - 118.28 mL Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d55d846-c833-4040-b02d-ac7783311dd6&amp;name=16e3bb49-35e7-40b9-9004-58f17a71dea6-02.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUOCINOLONE ACETONIDE 		
					</strong><br><span class="contentTableReg">fluocinolone acetonide oil</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:13925-507</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fluocinolone acetonide</strong> (fluocinolone acetonide) </td>
<td class="formItem">fluocinolone acetonide</td>
<td class="formItem">0.11 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL MYRISTATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LIGHT MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>OLETH-2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEANUT OIL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13925-507-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">118.28 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA019452</td>
<td class="formItem">08/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Seton Pharmaceuticals
							(828898002)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>16e3bb49-35e7-40b9-9004-58f17a71dea6</div>
<div>Set id: 8d55d846-c833-4040-b02d-ac7783311dd6</div>
<div>Version: 2</div>
<div>Effective Time: 20130823</div>
</div>
</div> <div class="DistributorName">Seton Pharmaceuticals</div></p>
</body></html>
